Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496289 | 1.00 | DUT (0.31) | DUT | |
| SCHEMBL17017287 | 0.84 | DUT (0.34) | DUT | |
| SCHEMBL18377988 | 0.84 | DUT (0.33) | DUT | |
| SCHEMBL6389772 | 0.81 | DUT (0.30) | DUT | |
| SCHEMBL18244588 | 0.81 | LPAR2 (0.31) | DUT | |
| SCHEMBL17997131 | 0.81 | LPAR2 (0.31) | DUT | |
| SCHEMBL6389768 | 0.81 | DUT (0.30) | DUT | |
| SCHEMBL18245124 | 0.81 | LPAR2 (0.31) | DUT | |
| SCHEMBL14244960 | 0.79 | DUT (0.33) | DUT | |
| SCHEMBL4484818 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458452-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | Bugworks Research, Inc. | 2019-09-26 | — | — | US | disclosed |
| US-9708236-B2 | Terminal alkene monoisomerization catalysts and methods | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708236-B2 | Terminal alkene monoisomerization catalysts and methods | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708236-B2 | Terminal alkene monoisomerization catalysts and methods | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231621-A1 | TERMINAL ALKENE MONOISOMERIZATION CATALYSTS AND METHODS | INF2, CPNE4, TEC | DUT 2132/4885 |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | ALPI, UROD, HLA-C | DUT 1057/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | DUT 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.